Figure 2
From: Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML
Sorafenib-resistant cell lines carry novel mutations. Genomic DNA from FLT3 inhibitor-sensitive and resistant MV4-11 and MOLM-13 cell lines was extracted using standard protocols. DNA was processed for exome sequencing. (a) Comparison of total SNVs per mega bases DNA. (b) Known mutations identified in different cell lines. Color code indicates observed allele depth. (c) Indels and point mutations were identified by comparing the generated sequence with that from the human reference genome. Genes with novel (not present in sorafenib-sensitive cells) indels and point mutations in both sorafenib-resistant MOLM-13 and MV4-11 cells are reported.
